Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Korea university anam hospital, Seoul, Korea, Republic of
Ajou University Hospital, Suwon, Korea, Republic of
Uludag University, Bursa, Turkey
Chonnam University Hwasun Hospital, Hwasun, Korea, Republic of
Hôpital Fondation Adolphe de Rothschild, Paris, France
Hopital Robert Debre, Paris, France
Centre Hospitalier Intercommunal Creteil (CHIC), Créteil, France
Medisch Centrum Haaglanden / Nederlandse Obesitas Kliniek, The Hague, Zuid Holland, Netherlands
Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
University Hospital Brno - FN Brno, Brno, Czech Republic, Czechia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.